异动解读 | 财报喜忧参半,Day One Biopharmaceuticals盘前暴跌14.24%

异动解读
Aug 06

生物制药公司Day One Biopharmaceuticals(股票代码:DAWN)周三盘前股价大跌14.24%,引发市场广泛关注。这一显著跌幅紧随公司发布的最新季度财报,其中包含了一些喜忧参半的业绩数据。

根据公司公布的截至6月30日的季度业绩报告,Day One Biopharmaceuticals的调整后每股亏损为0.29美元,优于分析师平均预期的0.36美元亏损。然而,公司营收虽同比大幅增长313.9%至3391万美元,但未能达到分析师预期的3530万美元。此外,公司本季度净亏损达3032万美元,这一持续亏损状况可能引发了市场对公司长期盈利能力的担忧。

尽管每股亏损好于预期,但投资者似乎对公司的整体财务表现感到失望,特别是营收未达预期可能是引发股价大跌的主要原因。值得注意的是,Day One Biopharmaceuticals今年迄今股价已下跌46.8%,这次的财报可能进一步打击了投资者信心。然而,分析师对公司仍保持乐观态度,平均评级为"买入",12个月目标价中位数为25美元,较当前股价仍有显著上涨空间。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10